Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases [NA]
This entry reports an ongoing clinical trial evaluating myeloablative preparative regimens for umbilical cord blood transplantation across s…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function [Phase 1]
Phase 1 trial assessing lymphodepleting total body irradiation plus cyclophosphamide before Carvykti (cilta-cel) CAR-T therapy in multiple m…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma [NA]
This entry describes an ongoing clinical trial evaluating the THRIVE-M psychosocial mobile application for patients with multiple myeloma; t…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating Iberdomide with Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) for relapsed or refractory multiple myelom…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma [Phase 1]
A Phase 1 clinical trial is investigating the safety and potential efficacy of CS1 CAR-T (WS-CART-CS1) for treating multiple myeloma and is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia [Phase 2]
Phase 2 clinical trial investigating IgPro20 to prevent infections in people with multiple myeloma and hypogammaglobulinemia. The study is c…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating cord blood-derived NK cells engineered with NY-ESO-1 TCR/IL-15 for relapsed/refractory multiple myelo…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial is evaluating a CRISPR-edited anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, currently recrui…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating daratumumab in transplant-eligible patients with multiple myeloma has completed, with results posted.
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase clinical study evaluating a BCMA-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma; the trial status is no…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer Patients [NA]
A completed clinical trial evaluating an eHealth educational intervention to improve self-management and coping behaviors among cancer patie…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma [Phase 2]
This is a Phase 2 clinical trial of a personalized Selinexor-based therapy for relapsed/refractory multiple myeloma. The results have been p…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Planned Phase 1/2 safety study of SG2918 in patients with relapsed or refractory multiple myeloma, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders [NA]
This update reports the completed status of a trial assessing bone marrow and kidney transplant for patients with chronic kidney disease and…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study evaluating SIM0500 as a single-agent therapy in participants with relapsed or refractory multiple myeloma; recruitment is on…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating elranatamab in combination with cyclophosphamide for people with multiple myeloma is currently recruitin…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating the safety and potential usefulness of liposomal curcumin in patients with refractory or relapsed multip…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]
Phase 3 clinical trial comparing Linvoseltamab to the combination of Elotuzumab, Pomalidomide, and Dexamethasone in adults with relapsed/ref…
-
FDA approval · 2026-03-05FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating donor TGF-β NK cells in combination with Isatuximab for relapsed or refractory multiple myeloma; the study…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
This Phase 2 trial investigates minimal residual disease-guided maintenance therapy with belantamab mafodotin and lenalidomide after autolog…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial evaluating belantamab mafodotin in newly diagnosed, transplant-eligible multiple myeloma patients is active but not c…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Ixazomib + Pomalidomide + Dexamethasone In MM [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating ixazomib, pomalidomide, and dexamethasone in multiple myeloma, including relapsed disease. The study i…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse [Phase 2]
A Phase 2 trial investigating daratumumab as first-line therapy in transplant-ineligible multiple myeloma patients, with possible daratumuma…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation [Phase 3]
A Phase 3 study evaluating idecabtagene vicleucel with lenalidomide maintenance versus lenalidomide maintenance alone in adults with newly d…